Maya Jose R, Sadiq Mohammad Ali, Agarwal Aniruddha, Kaiser Peter K, Stoller Glenn L, Sepah Yasir Jamal, Nguyen Quan Dong
Dev Ophthalmol. 2016;55:391-8. doi: 10.1159/000439037. Epub 2015 Oct 26.
As demonstrated in the previous chapters of this textbook, retinal pharmacotherapeutics is a rapidly developing area. The enormous burden of disease in an aging population will hopefully be met by significant improvements in our understanding and treatment of disease processes such as age-related macular degeneration (AMD) and diabetic retinopathy. This chapter will provide perspectives on select anti-angiogenic drugs currently in development, as well as therapies directed against the complement cascade for the treatment of AMD, and an anti-inflammatory monoclonal antibody for the treatment of diabetic macular edema, among others, that have not been discussed elsewhere in this book. The mechanism of action of a number of drugs under discussion differs enough to have the potential to control neovascularization in several different ways, potentially allowing for more effective management of this process with fewer treatments.
正如本教科书前几章所表明的，视网膜药物治疗是一个快速发展的领域。随着人口老龄化，疾病负担巨大，希望通过我们对诸如年龄相关性黄斑变性（AMD）和糖尿病视网膜病变等疾病过程的理解和治疗取得重大进展来应对这一问题。本章将介绍目前正在研发的某些抗血管生成药物的相关情况，以及针对补体级联反应用于治疗AMD的疗法，还有用于治疗糖尿病性黄斑水肿的一种抗炎单克隆抗体等，这些内容在本书其他地方未作讨论。正在讨论的多种药物的作用机制差异足够大，有可能以几种不同方式控制新生血管形成，从而有可能用更少的治疗更有效地管理这一过程。
